MacroGenics Inc ( (MGNX) ) has released its Q2 earnings. Here is a breakdown of the information MacroGenics Inc presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
MacroGenics Inc., a clinical-stage biopharmaceutical company, specializes in developing innovative antibody-based therapeutics for cancer treatment, leveraging its proprietary antibody technology platforms. In its latest earnings report for the quarter ending June 30, 2025, MacroGenics Inc. reported total revenues of $22.2 million, a significant increase from $10.8 million in the same period last year. This growth was primarily driven by contract manufacturing revenues, which rose to $15.4 million from $2.9 million. However, the company recorded a net loss of $36.3 million, a decrease from the $55.7 million loss in the previous year, reflecting ongoing investments in research and development. Key financial highlights include a decline in cash and cash equivalents to $130.7 million from $182.8 million at the end of 2024, and a liability related to future royalties of $70.3 million following a royalty monetization arrangement. Looking ahead, MacroGenics remains focused on advancing its pipeline of product candidates and leveraging strategic collaborations to support its development efforts. The company anticipates that its current resources are sufficient to fund operations for at least the next twelve months, as it continues to explore additional financing options to support its growth strategy.